{"id":"telbivudine-or-lamivudine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL374731","moleculeType":"Small molecule","molecularWeight":"242.23"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"They do this by incorporating themselves into the viral DNA and causing chain termination during viral replication. This mechanism is specific to the treatment of viral infections such as hepatitis B.","oneSentence":"Telbivudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of viral DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:47.698Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Hepatitis B virus infection"}]},"trialDetails":[{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT01943799","phase":"PHASE2","title":"Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-13","conditions":"Chronic HBV Infection","enrollment":178},{"nctId":"NCT03778567","phase":"PHASE4","title":"Renoprotective Effects of Telbivudine in Chronic Hepatitis B","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08-01","conditions":"Hepatitis B, Chronic, Chronic Kidney Diseases","enrollment":31},{"nctId":"NCT02019966","phase":"","title":"A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-05-12","conditions":"The Difficult-to-treat Chronic Hepatitis B","enrollment":1020},{"nctId":"NCT00124241","phase":"PHASE2","title":"An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Novartis","startDate":"","conditions":"Hepatitis B","enrollment":""},{"nctId":"NCT02005146","phase":"","title":"Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2013-12","conditions":"Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues","enrollment":86},{"nctId":"NCT00057265","phase":"PHASE3","title":"A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-02","conditions":"Chronic Hepatitis B","enrollment":""},{"nctId":"NCT01788371","phase":"PHASE4","title":"Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus","status":"COMPLETED","sponsor":"Hua Zhang","startDate":"2009-03","conditions":"Hepatitis B Infection, Chronic Infection, Viremia","enrollment":700},{"nctId":"NCT01595633","phase":"PHASE4","title":"Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-03","conditions":"Chronic Hepatitis B","enrollment":124},{"nctId":"NCT01270165","phase":"PHASE3","title":"Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2010-06","conditions":"Chronic Hepatitis B","enrollment":110},{"nctId":"NCT00076336","phase":"PHASE3","title":"Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-12","conditions":"Hepatitis, Hepatitis B, Chronic, Cirrhosis","enrollment":232},{"nctId":"NCT00810524","phase":"PHASE4","title":"Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-01","conditions":"Hepatitis B, Chronic","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"telbivudine or lamivudine","genericName":"telbivudine or lamivudine","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telbivudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of viral DNA. Used for Chronic hepatitis B, Hepatitis B virus infection.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}